Alumis Inc. Common Stock
NASDAQ:ALMSBiotechnology
+$0.21 today
- Market cap
- $568.87M
- Beta
- -0.54
- P/E (TTM)
- -12.2
- EPS (TTM)
- -$1.90
Volume 2.01M
Average 1.31M
ALMS Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
Alumis Inc. Common StockNASDAQ: ALMS
Net Debt · Q2 FY2026 · quarter ended Jun 2026
Net debt remains negative
Q2 FY2026 net debt was -$27.28M, compared with -$112.98M a year earlier.
Context
- Net debt amounted to 4.9% of total assets at the end of Q2 FY2026, down 13.6 pp from a year earlier.
- Net debt grew in size in 1 of the last 3 fiscal years.
What to watch
Whether net debt keeps rising in the next quarterly balance sheet after a +75.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- (52.76M) USD
- Year-over-year change
- +62.0%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (52.76M) | +62.0% |
| FY2024 | 2024-12-31 | (138.8M) | -934.6% |
| FY2023 | 2023-12-31 | (13.42M) | +43.7% |
| FY2022 | 2022-12-31 | (23.83M) | — |
Net Debt vs competitors
How ALMS compares with its peers on the latest reported figures
- Peers report in different currencies, so net debt is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +75.9% is the 3rd highest of 9, against a peer median of +36.9%.
- Net debt amounts to 4.9% of total assets for ALMS, versus a peer median of 22.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $28.89M USD | +134.8% | — | 8.8% | |
| Mar 2026 | $21.31M USD | +38.9% | -9.4% | 4.2% | |
| Dec 2025 | -$3.55M USD | +1.8% | — | 30.9% | |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | -$10.69M USD | +34.8% | — | 10.1% |
| Mar 2026 | -€14.19M EUR | +69.5% | — | 29.0% | |
| Mar 2026 | -$22.66M USD | +81.8% | — | 22.7% | |
| Mar 2026 | -$26.68M USD | +4.3% | — | 13.4% | |
ALMSAlumis Inc. Common Stock | Jun 2026 | -$27.28M USD | +75.9% | — | 4.9% |
| Mar 2026 | -$49.49M USD | -42.3% | — | 74.4% | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | Sep 2025 | -€128.26M EUR | — | — | 77.4% |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding ALMS) | — | +36.9% | -9.4% | 22.7% | |
Competitors are the stored peer set for ALMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Alumis Inc. Common Stock
NASDAQ:ALMS
Intrinsic Alpha fair value
Locked
Current Price
$4.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.